

IDENIX PHARMACEUTICALS INC  
Form SC 13D/A  
August 12, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934  
(Amendment No. 11)\***

**Idenix Pharmaceuticals, Inc.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**45166R204**

(CUSIP Number)

**Rebecca Weston**

**Novartis Pharma AG**

**Lichtstrasse 35**

**CH-4056 Basel, Switzerland**

**+41 61 324 7015**

**With a copy to:**

**Peter Harwich**

**Allen & Overy LLP**

Edgar Filing: IDENIX PHARMACEUTICALS INC - Form SC 13D/A

**1221 Avenue of the Americas**

**New York, New York 10020**

**+1 212 610 6300**

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

**August 5, 2014**

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

Edgar Filing: IDENIX PHARMACEUTICALS INC - Form SC 13D/A

CUSIP No. 45166R204

- |     |  |                               |
|-----|--|-------------------------------|
| 1.  | Name of Reporting Person<br>Novartis AG  |                               |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                      |                               |
|     | (a)  | <input type="radio"/>         |
|     | (b)  | <input type="radio"/>         |
| 3.  | SEC Use Only   |                               |
| 4.  | Source of Funds (See Instructions)<br>N/A  |                               |
| 5.  | Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  | <input type="radio"/>         |
| 6.  | Citizenship or Place of Organization<br>Switzerland                                      |                               |
|     | 7.   | Sole Voting Power<br>0        |
|     | 8.   | Shared Voting Power<br>0      |
|     | 9.   | Sole Dispositive Power<br>0   |
|     | 10.  | Shared Dispositive Power<br>0 |
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person                             | 0                             |
| 12. | Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | <input type="radio"/>         |
| 13. | Percent of Class Represented by Amount in Row (11)<br>0%                                 |                               |
| 14. | Type of Reporting Person (See Instructions)<br>CO  |                               |

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

Edgar Filing: IDENIX PHARMACEUTICALS INC - Form SC 13D/A

CUSIP No. 45166R204

- |     |  |                               |
|-----|--|-------------------------------|
| 1.  | Name of Reporting Person<br>Novartis Pharma AG   |                               |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                      |                               |
|     | (a)  | <input type="radio"/>         |
|     | (b)  | <input type="radio"/>         |
| 3.  | SEC Use Only   |                               |
| 4.  | Source of Funds (See Instructions)<br>N/A  |                               |
| 5.  | Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  | <input type="radio"/>         |
| 6.  | Citizenship or Place of Organization<br>Switzerland                                      |                               |
|     | 7.   | Sole Voting Power<br>0        |
|     | 8.   | Shared Voting Power<br>0      |
|     | 9.   | Sole Dispositive Power<br>0   |
|     | 10.  | Shared Dispositive Power<br>0 |
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person                             | 0                             |
| 12. | Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | <input type="radio"/>         |
| 13. | Percent of Class Represented by Amount in Row (11)<br>0%                                 |                               |
| 14. | Type of Reporting Person (See Instructions)<br>CO  |                               |

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

## **Introductory Statement**

This Amendment No. 11 (this **Amendment** ) amends the Schedule 13D initially filed with the Securities and Exchange Commission on August 6, 2004, as previously amended on September 7, 2005, November 2, 2005, May 20, 2009, June 18, 2010, April 20, 2011, December 15, 2011, August 10, 2012, February 14, 2014, March 28, 2014 and July 28, 2014 (the **Original Schedule 13D** ) relating to shares of the Common Stock, \$0.001 par value per share (the **Common Stock** ), of Idenix Pharmaceuticals, Inc., a Delaware corporation (the **Issuer** ). All information reported in the Original Schedule 13D remains in effect except to the extent that it is amended or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment shall have the respective meanings set forth with respect thereto in the Original Schedule 13D.

## **Item 4. Purpose of Transaction**

The disclosure in Item 4 of the Original Schedule 13D is hereby amended as follows.

On August 5, 2014, Merck announced the successful completion of the Offer and the acceptance of all tendered shares of Common Stock for payment in accordance with the terms of the Offer.

**SIGNATURE**

After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

Date: August 12, 2014

NOVARTIS AG

By: /s/ Christian Rehm  
Name: Christian Rehm  
Title: Authorized Signatory

By: /s/ Laurent Sigismondi  
Name: Laurent Sigismondi  
Title: Authorized Signatory

NOVARTIS PHARMA AG

By: /s/ Marc Ceulemans  
Name: Marc Ceulemans  
Title: Head Strategic Venture Capital Fund & Pharma  
Equities

By: /s/ Rebecca Weston  
Name: Rebecca Weston  
Title: Senior Legal Counsel

**ATTENTION**

**Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value \$0.001 per share, of Idenix Pharmaceuticals, Inc., a Delaware corporation.

Date: August 12, 2014

**NOVARTIS AG**

By: /s/ Christian Rehm  
Name: Christian Rehm  
Title: Authorized Signatory

By: /s/ Laurent Sigismondi  
Name: Laurent Sigismondi  
Title: Authorized Signatory

**NOVARTIS PHARMA AG**

By: /s/ Marc Ceulemans  
Name: Marc Ceulemans  
Title: Head Strategic Venture Capital Fund & Pharma Equities

By: /s/ Rebecca Weston  
Name: Rebecca Weston  
Title: Senior Legal Counsel